Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 4Sexuality 2Sexual Dysfunction, Physiological 2Erectile Dysfunction 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Urogenital Neoplasms 1Solid Tumor 1Sarcoma 1Rectal Neoplasms 1Radiation Injuries 1Postoperative Complications 1Neurologic Manifestations 1Lymphatic Abnormalities 1Lymphangioma 1Infertility 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 52Cyclophosphamide 42fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 41Whole-Body Irradiation 26Mycophenolic Acid 25Cyclosporine 21Bortezomib 21Dexamethasone 19Busulfan 18Tacrolimus 17Etoposide 17Filgrastim 15Antilymphocyte Serum 14Methotrexate 13Melphalan 13ibrutinib 12Radiotherapy 11Calcium Dobesilate 9Sirolimus 8Lenalidomide 8Cyclosporins 8Methylprednisolone 7Flow Cytometry 7Everolimus 7Carboplatin 7ibritumomab tiuxetan 6zanubrutinib 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Waldenstrom Macroglobulinemia × Sildenafil Citrate × Clear all
NCT00165295 2011-06-27

Sildenafil Citrate in Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Completed
30 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡